Literature DB >> 15223473

Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies.

Ben M Tsai1, Meijing Wang, Mark W Turrentine, Yousuf Mahomed, John W Brown, Daniel R Meldrum.   

Abstract

Hypoxic pulmonary vasoconstriction is postulated to be an adaptive mechanism to match lung perfusion with ventilation; however, the consequences of the maladaptive effects of pulmonary vasoconstriction represent formidable therapeutic challenges. Understanding the basic mechanisms of hypoxic pulmonary vasoconstriction will enhance the assimilation of translational research into clinical practice. The purposes of this review are to (1) define basic mechanisms of pulmonary vasoconstriction and vasorelaxation; (2) delineate the biphasic contractile response to hypoxia; (3) critically examine data that support the mediator hypothesis versus the ion channel hypothesis; and (4) explore potential mechanistic-based therapies for hypoxic pulmonary vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223473     DOI: 10.1016/j.athoracsur.2003.11.035

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  CCN1 suppresses pulmonary vascular smooth muscle contraction in response to hypoxia.

Authors:  Seon-Jin Lee; Meng Zhang; Kebin Hu; Ling Lin; Duo Zhang; Yang Jin
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 2.  Influence of Spontaneous and Mechanical Ventilation on Frequency-Based Measures of Heart Rate Variability.

Authors:  Khlood Bubshait; Yasmine Alabbasi
Journal:  Crit Care Res Pract       Date:  2021-12-26

3.  Ethyl pyruvate inhibits hypoxic pulmonary vasoconstriction and attenuates pulmonary artery cytokine expression.

Authors:  Ben M Tsai; Tim Lahm; Eric D Morrell; Paul R Crisostomo; Jeffrey Poynter; Meijing Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

4.  Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction.

Authors:  Brent M Toney; Amanda J Fisher; Marjorie Albrecht; Angelia D Lockett; Robert G Presson; Irina Petrache; Tim Lahm
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

5.  Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.

Authors:  Veronica Franco; Elisa A Bradley; Roberto Badagliacca; Aarthi Sabanayagam; Saurabh Rajpal; Lauren T Lastinger; Curt J Daniels; J Shaun Smith; Raymond L Benza
Journal:  Pulm Circ       Date:  2020-11-20       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.